Ruxolitinib (phosphate) [1092939-17-7]
Cat# HY-50858-200mg
Size : 200mg
Brand : MedChemExpress
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
- Protocol 1
Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.75 mg/mL (6.80 mM); Clear solution
- Protocol 2
Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.75 mg/mL (6.80 mM); Clear solution
For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
- Protocol 1
Add each solvent one by one: 0.5% MC 0.5% Tween-80
Solubility: 10 mg/mL (24.73 mM); Suspended solution; Need ultrasonic
Dosage
mg/kgAnimal weight
(per animal)
Dosing volume
(per animal)
Number of animals
*In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
Purity: 99.98%
-
[1]. Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117. [Content Brief]
[2]. Fleischman AG, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013 Nov 21;122(22):3628-31. [Content Brief]
[3]. de Bock CE, et al. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. Cancer Discov. 2018 May;8(5):616-631. [Content Brief]
Complete Stock Solution Preparation Table
* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
H2O / DMSO | 1 mM | 2.4730 mL | 12.3652 mL | 24.7304 mL | 61.8261 mL |
5 mM | 0.4946 mL | 2.4730 mL | 4.9461 mL | 12.3652 mL | |
10 mM | 0.2473 mL | 1.2365 mL | 2.4730 mL | 6.1826 mL | |
15 mM | 0.1649 mL | 0.8243 mL | 1.6487 mL | 4.1217 mL | |
20 mM | 0.1237 mL | 0.6183 mL | 1.2365 mL | 3.0913 mL | |
DMSO | 25 mM | 0.0989 mL | 0.4946 mL | 0.9892 mL | 2.4730 mL |
30 mM | 0.0824 mL | 0.4122 mL | 0.8243 mL | 2.0609 mL | |
40 mM | 0.0618 mL | 0.3091 mL | 0.6183 mL | 1.5457 mL | |
50 mM | 0.0495 mL | 0.2473 mL | 0.4946 mL | 1.2365 mL | |
60 mM | 0.0412 mL | 0.2061 mL | 0.4122 mL | 1.0304 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Ruxolitinib phosphate Related Classifications
- Epigenetics Stem Cell/Wnt Protein Tyrosine Kinase/RTK JAK/STAT Signaling Autophagy
- JAK Autophagy Mitophagy
-
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Keywords:
Ruxolitinib1092939-17-7INCB018424INCB 018424INCB-018424JAKAutophagyMitophagyJanus kinaseMitochondrial AutophagyInhibitorinhibitorinhibit